Surviving BioTech: How the Game is Played – Phase Funding, Drug Approvals and Resulting Revenue

Surviving BioTech: How the Game is Played – Phase Funding, Drug Approvals and
                              Resulting Revenue

  PR Newswire

  NEW YORK, January 14, 2013

NEW YORK, January 14, 2013 /PRNewswire/ --

The biotechnology industry is a high-risk, high-reward scenario. It is an
unstable and unpredictable sector, primarily due to the scientifically
intensive nature of the operation of biotech companies. Developing new types
of drugs is promising, and to minimize risk, partnerships must be established
in order to increase funds and revenues.

Learning to survive in one of the most volatile industries in the market
today, VIVUS, Inc. (NASDAQ: VVUS) [ Full Research Report ] ^(1) and Peregrine
Pharmaceuticals, Inc. (NASDAQ: PPHM) [ Free Research Report ] ^(2) are
learning to play the game. Although the industry is not without significant
risk, for those who get it right, the rewards can be astounding. Revenues
earned by the global biotechnology industry are continuously increasing and
are likely to continue on this trend of growth.

The industry is expected to exceed $320 billion by 2015. Factors that also
help boost this industry are increased access to health insurance, the
continued introduction of expensive new drugs, as well as the fact that the
population today is rapidly aging.

As biotech companies are delivering new levels of health and sustainability,
increased research and development (R&D) funding is needed so that they can
discover and develop more advanced drugs to fulfill the health needs of
consumers. As most biotech firms are small and private companies, partnerships
with major pharmaceuticals are crucial to be able to increase R&D investments.

VIVUS, Inc. reported its third quarter financial results, recognizing net
product revenues of $41,000 from prescriptions shipped from certified
pharmacies to patients. VIVUS reported a net loss of $40.4 million, or $0.40
per share, as compared to last year's loss of $8.6 million, or $0.10 per
share. The increase in net loss is due to increased selling, general and
administrative expenses related to pre-commercialization and commercialization
activities for Qsymia.

Peregrine Pharmaceuticals, Inc. reported its second quarter of fiscal year
2013 financial results in which the total revenues were $6,139,000, compared
to $4,232,000 of the second quarter of FY 2012. The increase was due to the
contract manufacturing revenue generated by Peregrine Pharmaceuticals' bio
manufacturing subsidiary, Acid Bioservices, which generated
contract-manufacturing revenue of $6,061,000 for the second quarter of FY
2013, compared to FY 2012's $4,154,000. Contract manufacturing revenue is
expected to be at least $18 million for FY 2013.

To further understand how the likelihood of drug approvals influences the
manner in which companies leverage their future product pipelines, while at
the same time establish cash-flowing relationships with larger brands, readers
may explore our complete research reports below.

Reference Links:

^(1) The Full Research Report on VIVUS, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [
http://www.NationalTradersAssociation.org/r/entire_report/d5b8_VVUS ]

^(2) The Free Research Report on Peregrine Pharmaceuticals, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at: [
http://www.NationalTradersAssociation.org/r/entire_report/f9ad_PPHM ]

Consider National Traders Association

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop -- long before they become
the next top news on major financial networks.

Contact: Demi Lapierre Email : press@NationalTradersAssociation.org Main :
+1(702)-212-4493